Premium
Pioglitazone decreases adiposity and increases food intake in a model of PCOS
Author(s) -
Whigham Leah D,
Bruns Cristin M,
Colman Ricki J,
Shumway Nora K,
Abbott David H
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1058-b
Polycystic ovary syndrome (PCOS), a common endocrine disorder affecting ~10% women in their reproductive years, is the leading cause of premature type 2 diabetes in young women. Prenatally androgenized (PA) rhesus monkeys express a phenotype similar to PCOS women. The objective of this study was to determine the effect of pioglitazone, an insulin sensitizer, on body composition and food intake in a group of PA monkeys compared to controls. Adult females (4 controls, 7 PA) were treated daily with placebo for 6–7 months, followed by at least 90 d of no treatment (to avoid seasonal oligomenorrhea), and then 6–7 months of daily treatment with pioglitazone (3mg/kg). Monkeys were fed a standard chow ad libitum throughout the study. Body composition was analyzed by DXA. Calorie intake was increased significantly during months 5 and 6 of pioglitazone treatment in both female groups. Total weight, total fat, and abdominal fat were greater in controls vs. PAs. PA females lost total fat on pioglitazone but not placebo. In conclusion, the body composition effects of pioglitazone differ depending on the presence or absence of a PCOS‐like phenotype. Support for this study was provided by NIH grant R01 RR013635.